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Background—Invasive fungal infections remain problematic in immunosuppressed allogeneic 
stem cell transplant recipients and the use of corticosteroids for the treatment of graft-versus-host-
disease can increase the risk three-fold. Although antifungal prophylaxis has been shown to 
decrease the incidence of infection, the optimal antifungal prophylactic regimen in this patient 
population has yet to be identified. Since early diagnosis of fungal infections might not be possible 
and the treatment of established fungal infections might be difficult and associated with high 
infection related mortality, prevention has become an important strategy in reducing overall 
morbidity and mortality. While triazoles are the preferred agents, some patients are unable to 
tolerate them and an alternative drug is warranted.
Objectives—To assess the tolerability of once weekly liposomal amphotericin B as a 
prophylactic strategy in patients undergoing stem cell transplantation by evaluating any adverse 
events leading to its discontinuation. In terms of efficacy, to also compare the outcome and 
incidence of invasive fungal infections in patients who received amphotericin B, triazoles, and 
echinocandins.
Results—A total of 101 allogeneic transplant recipients receiving corticosteroids for the 
treatment of graft-versus-host-disease and antifungal prophylaxis were evaluated from August 
2009 to September 2012. Liposomal amphotericin B 3 mg/kg intravenous once weekly was found 
to be well-tolerated. The incidence of invasive fungal infections was 19%, 17%, and 7% in the 
liposomal amphotericin B, echinocandin, and triazole groups, respectively. Two deaths occurred 
in the liposomal amphotericin B group and one death occurred in the echinocandin group. None of 
the deaths were fungal infection-related.
Conclusion—Antifungal prophylaxis with liposomal amphotericin B was well-tolerated but the 
incidence of invasive fungal infections in patients receiving liposomal amphotericin B was higher 
than other antifungal agents in this study. The optimal dose and schedule of liposomal 
amphotericin B for antifungal prophylaxis in this patient population is still not known and 
considering its broad spectrum activity, prospective trials in comparison to triazoles are warranted.
Keywords
Liposomal amphotericin B; graft-versus-host-disease; invasive fungal infections; hematopoietic 
stem cell transplant; corticosteroids; prophylaxis
Introduction
Invasive fungal infections (IFIs) can cause significant morbidity and mortality in allogeneic 
hematopoietic stem cell transplant (HSCT) recipients. Depending on risk factors, the rate of 
infection is between 10 and 25%, with fatalities between 35 to 50% for invasive candidiasis 
and 65 to 90% for invasive aspergillosis.1,2 There are many well-known risk factors for the 
development of infection in this patient population. The use of corticosteroids for the 
treatment of graft-versus-host disease (GvHD) increases this risk three-fold.1,3–5 To reduce 
the morbidity and mortality associated with this complication, several prophylactic 
antifungal regimens have been used and studied including triazoles, echinocandins, and 
amphotericin B. While triazoles are available orally and have the most evidence to support 
its role as prophylaxis, barriers such as hepatic dysfunction, drug interactions, and the ability 
to obtain therapy can limit their use.6 Furthermore, triazole-based prophylaxis may result in 
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an increase in invasive aspergillosis compared to invasive candidiasis.4 Although 
echinocandins have been shown to be effective in preventing IFIs, there is still a need for 
effective broad spectrum antifungal prophylaxis as the incidence of breakthrough infections 
were still high with echinocandins.7
Amphotericin B (AmB) is a polyene antifungal with a wide spectrum of activity against 
yeasts and molds.3,4,8 It binds to sterols on the cytoplasmic membrane to increase 
permeability, resulting in leakage of molecules leading to cell death. Resistance is rare but 
can occur through mutations in the ergosterol synthesis pathway. For many years, AmB has 
been the gold standard for the treatment of IFIs. However, the use of AmB often produces 
nephrotoxicity and infusion-related adverse effects, limiting its administration. Reduced 
toxicity has been observed with newer lipid formulations. Liposomal amphotericin B 
(LAmB) is a unilamellar formulation of AmB that allows for the delivery of higher doses 
with decreased toxicity.9 LAmB, compared to AmB, has a longer half-life (174 hours versus 
48 hours) which allows for less frequent dosing.8,9 In addition, its intravenous formulation 
makes it an attractive option in patients unable to tolerate oral medications.
To our knowledge, there is no literature to support an optimal dosing regimen for LAmB as 
a prophylactic agent in the setting of HSCT. Several studies evaluating different 
amphotericin B formulations for fungal prophylaxis have yielded conflicting results, likely 
due to the differences in study design, patient population, and dosing regimen.10–14 
Specifically, few studies have evaluated LAmB or compared it to triazoles or echinocandins 
for fungal prophylaxis in HSCT patients receiving steroids for the treatment of GvHD. 
Chaftari et al. prospectively compared amphotericin B lipid complex (ABLC) 7.5 mg/kg 
intravenous once weekly as an alternative to posaconazole for prophylaxis in HSCT 
patients.15 Although there were no differences in the incidence of IFIs between the ABLC 
versus posaconazole group (5% versus 0%, p=0.48), the use of ABLC for fungal 
prophylaxis in HSCT patients could not be recommended due to a significantly higher rate 
of nephrotoxicity. A different outcome was observed when Cheikh et al. performed a single 
center, retrospective comparison of LAmB 7.5 mg/kg intravenous once weekly to various 
azoles and caspofungin for fungal prophylaxis in allogeneic HSCT patients being treated 
with high dose steroids for GvHD.16 Investigators found that LAmB, compared to the other 
prophylaxis group, significantly decreased IFIs (8% at 1 year versus 36% at 1 year, p=0.008) 
and fungal related mortality (0% at 1 year versus 14% at 1 year, p=0.005). It was concluded 
that LAmB was effective and well tolerated in this patient population. It has been reported 
that LAmB is associated with fewer infusion-related reactions and less nephrotoxicity which 
could explain the different outcomes in these two studies.5 Given the results presented, the 
role and dose of amphotericin B for fungal prophylaxis in HSCT patients still remains 
unclear.
Prior to available published data supporting LAmB 7.5 mg/kg intravenous once weekly, our 
institution has been using LAmB 3 mg/kg intravenous once weekly since 2008 as an 
alternative for antifungal prophylaxis in patients who are unable to tolerate or receive 
triazoles or echinocandins and were being treated for GvHD with corticosteroids 
(prednisone ≥ 20 mg daily or equivalent). All of the patients were dosed using their actual 
body weight. The purpose of this study was to determine the tolerability of LAmB as 
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antifungal prophylaxis in HSCT patients and to compare the outcome of LAmB 3 mg/kg 
intravenous once weekly to mold-active triazoles and echinocandins for the prevention of 
IFIs in HSCT patients receiving corticosteroids (prednisone ≥ 20 mg daily or equivalent) for 
the treatment of GvHD.
Patients and methods
Study design and patients are included in Figure 1. A single center comparative chart review 
was performed at our institution. Patients treated with steroids (prednisone ≥ 20 mg daily or 
equivalent) for acute or chronic GvHD after allogeneic stem cell transplantation during the 
time period August 2009 to September 2012 were retrospectively identified. Patients were 
then grouped according to the fungal prophylactic therapy they received. Those who 
previously received a triazole but were switched to an echinocandin or LAmB were included 
in the arm of the agent they were switched to. This study was approved by the institutional 
review board.
Allogeneic stem cell transplant recipients were included in the study if they received single 
agent fungal prophylaxis at the time of GvHD treatment. Patients who received at least one 
dose of LAmB or one week of echinocandin and triazole prophylaxis were eligible for study 
inclusion. Patients with a prior history of IFIs were also included in the study. Patients were 
excluded if they were treated for a fungal infection in the previous 28 days. Patients were 
followed until discontinuation of prophylaxis or until proven or presumed fungal infection 
requiring treatment. Rates of IFIs were compared in each arm. Other baseline information 
collected included transplant conditioning regimen, duration of neutropenia, use of 
immunosuppressive agents such as alemtuzumab and fludarabine, GvHD prophylaxis 
regimen, cytomegalovirus (CMV) serostatus, dose and duration of steroid, and indications 
for not using a triazole for prophylaxis.
Data analysis
The primary end point of this study was to assess the tolerability of LAmB. All patients who 
received one dose of LAmB were included in the analysis. Any adverse events that led to the 
discontinuation of LAmB were evaluated. The secondary objectives were to compare the 
incidence of IFIs in each arm. Patients who received at least one week of antifungal 
prophylactic therapy were assessed. In addition to descriptive statistics, Fisher’s exact test 
was used to compare the differences between all groups in baseline characteristics and 
incidence of IFIs. Analysis of variance (ANOVA) was used to compare duration of 
antifungal prophylaxis.
Definitions
Outcomes were assessed by incidence of IFIs requiring treatment. IFIs were categorized as 
proven, probable, and possible as defined by the revised definitions by the Invasive Fungal 
Infections Cooperative Group of the European Organization for Research and Treatment of 
Cancer (EORTC).17
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Proven IFIs were defined as clinical signs and symptoms and radiologic findings suggestive 
of infection in the presence of the proper host factors with histopathologic or microbiologic 
documentation of disease from tissue sample biopsies. Host factors include duration of 
neutropenia, allogeneic stem cell transplant, prednisone > 0.3 mg/kg/day, and T-cell 
suppression.
Probable IFIs were defined as clinical signs and symptoms and radiologic findings 
suggestive of infection in the presence of a mycological criteria such as a positive culture 
from bronchoalveolar lavage fluid, sputum or brush samples, or the detection of serum 
galactomannan antigen in patients with appropriate host factors.
Possible IFIs were defined as clinical signs and symptoms and radiologic findings 
suggestive of infection in the absence of a mycological criteria in patients with appropriate 
host factors.
Results
Of 101 patients evaluated, the LAmB prophylaxis group included 16 patients who received 
LAmB 3 mg/kg intravenous once weekly. The echinocandin group included 12 patients 
(caspofungin, 10 patients; micafungin, 2 patients) and the triazole group included 73 patients 
(voriconazole, 30 patients; posaconazole, 43 patients).
Baseline characteristics of all patients are included in Table 1. All groups were comparable 
as far as age, underlying malignancy, conditioning regimen intensity, GvHD prophylactic 
regimen, and CMV serostatus. Additionally, no differences were noted in the incidence or 
type of GvHD. Four patients in the LAmB group were treated with alemtuzumab post-
transplant for GvHD while no patients in the other groups received it. A higher percentage 
of patients in the echinocandin group experienced prolonged and profound neutropenia and 
this was statistically different between the three groups. As shown in Table 2, the steroid 
dose was similar with the majority of patients requiring ≥ 1 mg/kg corticosteroid at initiation 
of antifungal prophylaxis and the mean days of antifungal prophylaxis were similar in all 
three groups.
LAmB 3 mg/kg intravenous once weekly was well tolerated; there were no reported adverse 
events such as nephrotoxicity, infusion reactions, or electrolyte disturbances that led to its 
discontinuation. Therapy was discontinued in one patient due to an adverse event of back 
pain which resolved when the infusion was stopped.
As presented in Table 3, the incidence of IFIs was highest in the LAmB group at 19%, 
followed by the echinocandin group at 17%, and lowest in the triazole group at 5% 
(p=0.145). There were no proven infections in any of the treatment groups. According to the 
diagnostic definition of the EORTC consensus group, there were three possible infections in 
the LAmB group. In the echinocandin group, there was one possible and one probable 
infection. Both patients received caspofungin. In the triazole group, there were three 
possible infections and one probable infection.
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Although there were four deaths that occurred in patients who were diagnosed with IFIs, 
none were fungal infection-related. Two of the deaths that occurred in the LAmB group 
were due to bacterial infections and GvHD. The one death that occurred in the echinocandin 
group was due to GvHD, Methicillin-resistant Staphylococcus aureus pneumonia, and CMV 
infection. The one death that occurred in the triazole group was due to Pseudomonas 
pneumonia.
The most common reasons for not using a mold-active triazole are presented in Table 4. 
Hepatic dysfunction was the most common barrier, followed by the patient’s inability to pay 
for therapy. Other reasons included additive potential for QTc interval prolongation, non-
compliance, and use of LAmB as secondary prophylaxis following successful treatment 
response of a previous fungal infection. Although drug interactions with azoles and 
calcineurin inhibitors are well known, this did not prohibit azole use as our institution has an 
algorithm in place that incorporates a preemptive dose-reduction strategy of the calcineurin 
inhibitor, followed by monitoring for adverse effects in addition to twice weekly drug levels. 
This prevented any event, such as renal or neurotoxicity, that would lead to the 
discontinuation of the azole or calcineurin inhibitor.
The most common reasons for discontinuation of antifungal prophylaxis are outlined in 
Table 5. Steroid dose less than prednisone 20 mg daily (or equivalent) was the most 
common reason, followed by not being able to obtain triazole therapy. In the LAmB group, 
therapy was discontinued after a patient experienced progression of disease. In the 
echinocandin group, one patient died of cardiac arrest and one patient pursued hospice care. 
In the triazole group, two patients pursued hospice and one patient experienced 
thrombocytopenia and all medications were held. Five patients remained on prophylactic 
triazole therapy at the conclusion of the study and were not included in this part of the 
analysis.
Discussion
The prevention of IFIs in immunosuppressed allogeneic stem cell transplant recipients with 
GvHD remains a challenge as there are many barriers than can limit the use of triazoles. 
AmB has a broad spectrum of activity against molds and yeasts including Candida, 
Aspergillus, and Zygomycetes, offering an advantage over triazoles or echinocandins. 
Furthermore, lipid-based amphotericin B products have been associated with decreased 
incidences of nephrotoxicity compared to conventional amphotericin B and is being used at 
some centers as an alternative antifungal prophylactic agent. This study evaluated the 
tolerability and outcome of once weekly prophylactic LAmB 3 mg/kg administered 
intravenously to adult patients receiving corticosteroids for the treatment of GvHD after 
allogeneic stem cell transplant. To our knowledge, the dose of LAmB 3 mg/kg intravenous 
once weekly has not been evaluated in published literature and in our study, there were no 
adverse events leading to discontinuation of therapy compared to a higher dose of LAmB 
7.5 mg/kg intravenous once weekly studied by Cheikh et al. which reported a 12% incidence 
of reversible nephrotoxicity leading to temporary treatment discontinuation.16 Furthermore, 
our study was consistent with literature supporting liposomal amphotericin B to be less 
nephrotoxic than the lipid complex formulation where Chaftari et al. observed therapy 
Tran et al. Page 6













discontinuation in 53% of patients due to nephrotoxicity at a dose of 7.5 mg/kg intravenous 
once weekly.15
In addition to high dose corticosteroids, prolonged and profound neutropenia can further 
lead to IFIs regardless of prophylaxis as patients no longer have competent T cells to fight 
off infection.3 Our study shows that there was a significant difference between the three 
groups with more patients in the echinocandin and LAmB group experiencing prolonged 
and profound neutropenia than the triazole group (42%, 12.5%, and 7%, p=0.005) possibly 
contributing to higher rates of IFIs. Furthermore, the use of agents such as alemtuzumab or 
fludarabine can have prolonged and profound lymphocyte depleting effects, thereby 
increasing the risk for infections. Our study observed a higher incidence of IFIs in the 
LAmB group that may be explained by the use of alemtuzumab by four patients compared to 
no patients in the echinocandin and triazole group.
The epidemiology of IFIs has evolved as transplant practices and prophylactic strategies 
have changed over the last several decades. In our study, the incidence of IFIs in the triazole 
group was 5% which is consistent with Chaftari et al. and other literature reports ranging 
from 2 to 9% in patients receiving mold-active agents.12,15,18–21 These findings were not 
supported by Cheikh et al. because the majority of the patients in the azole and echinocandin 
prophylaxis group (71%) received the non-mold active agent fluconazole. However, the 
incidence of IFIs in our LAmB group was 19%, which is higher than incidences reported by 
Chaftari et al. and Cheikh et al. at 5% and 8%, respectively.15,16 In spite of this, a 
statistically significant difference was not detected in our study and it can be argued that 
LAmB is comparable to triazoles in preventing IFIs in this patient population but larger 
studies are needed to determine this.
Potential advantages of using LAmB include decreased cost and the convenience of less 
frequent dosing, as well as a different side effect profile than triazoles. One of the drawbacks 
of using a triazole in the outpatient setting is the out-of-pocket expense to the patient, which 
could amount to thousands of dollars a month, possibly leading to non-compliance.22 In 
these situations where the patient is unable to pay, an alternative prophylactic agent is 
needed as the cost of preventing an IFI in these high risk patients outweighs the treatment of 
it. Furthermore, compared to daily dosing of echinocandins and triazoles, once weekly 
LAmB may be a convenient intravenous option for patients, decreasing chair time and 
increasing compliance.
In our study, the mean duration of prophylaxis was comparable to triazoles, and LAmB 
could be an acceptable prophylactic agent that can be administered for long periods of time 
to further improve the safety and outcome of allogeneic stem cell transplants. The study is 
subject to several limitations. The first is the small sample size that made it difficult to detect 
statistically significant differences. Second, the retrospective analysis made it challenging to 
capture compliance and all adverse events, especially in patients who received therapy 
through home health or their local facility. During the study period, the formulary switched 
from caspofungin to micafungin. Although used interchangeably by some clinicians, 
micafungin is the only echinocandin approved in the prophylactic setting and this could have 
resulted in potentially different outcomes in the echinocandin group. Furthermore, the 
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possibility that IFIs were over-diagnosed cannot be excluded as none of the infections were 
proven. This situation may arise because this patient population is at very high risk for 
fungal infections and the threshold for initiating antifungal treatment is low. Additionally, it 
should be noted that the LAmB group consisted of only possible infections.
Conclusion
Although LAmB 3 mg/kg once weekly is tolerable, larger studies are needed to evaluate its 
efficacy. The optimal dose and schedule is still not known and considering the broad 
spectrum activity of LAmB, prospective trials in comparison to triazoles are warranted.
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Table 1
Baseline patient characteristics
LAmB (n=16) Echinocandin (n=12) Triazole (n=73) P
Age, Years (mean) 45.8 47.5 50 NS
Underlying disease NS
 Acute leukemias/MDS 11 (69%) 10 (83.3%) 46 (63%)
 Chronic leukemias 2 (12.5%) 1 (8.3%) 12 (16.5%)
 Lymphomas 3 (18.5%) 1 (8.3%) 15 (21.5%)
Conditioning Regimen NS
 Myeloablative 11 69%) 4 (33%) 38 (52%)
 Nonmyeloablative 3 (18.5%) 6 (50%) 18 (25%)
 Reduced intensity 2 (12.5%) 2 (17%) 17 (23%)
GvHD Prophylaxis Regimen NS
 CSA/MMF 1 (6%) 2 (17%) 5 (7%)
 FK/MMF 2 (12.5%) 3 (25%) 19 (26%)
 FK/MTX 11 (69%) 4 (33%) 36 (49%)
 ATG-based/other 2 (12.5%) 3 (25%) 13 (18%)
Immunosuppressive Agents+
 Alemtuzumab 4 (25%) 0 (0%) 0 (0%) NS
Prolonged Grade 4 Neutropenia++ 2 (12.5%) 5 (42%) 5 (7%) 0.005
CMV Status NS
 D+/R+ 6 (37.5%) 4 (33%) 19 (26%)
 D+/R− 4 (25%) 4 (33%) 15 (20.5%)
 D−/R− 4 (25%) 2 (17%) 26 (35.5%)
 D−/R+ 2 (12.5%) 2 (17%) 13 (18%)
GvHD NS
 Acute 8 (50%) 7 (58%) 47 (64%)
 Chronic 8 (50%) 5 (42%) 26 (36%)
MDS=Myelodysplastic syndrome
CSA=Cyclosporine, MMF=Mycophenolate Mofetil, FK=Tacrolimus, MTX=Methotrexate, ATG=Antithymocyte Globulin





Lasting more than 7 days
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Table 2
Dose of corticosteroid therapy and duration of antifungal prophylaxis
LAmB (n=16) Echinocandin (n=12) Triazole (n=73) P
Steroid Dose
 < 1 mg/kg/day 2 (12.5%) 0 (0%) 13 (18%)
 ≥1 mg/kg/day 14 (87.5%) 12 (100%) 60 (82%)
Prophylaxis Days (mean) 59.5 34.5 75 0.125
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Table 3
Incidence of invasive fungal infections
LAmB (n=16) Echinocandin (n=12) Triazole (n=73) P
Proven 0 (0%) 0 (0%) 0 (0%)
Probable 0 (0%) 2 (17%) 1 (1%)
Possible 3 (19%) 0 (0%) 3 (4%)
Total 3 (19%) 2 (17%) 4 (5%) 0.145
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Table 4
Barriers to obtaining triazole therapy
LAmB (n=16) Echinocandin (n=12) Triazole (n=73)
Hepatic dysfunction 11 8 N/A
Insurance 2 3 N/A
Drug interactions 1 1 N/A
Other 2 0 N/A
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Table 5
Reasons for discontinuation of antifungal prophylaxis
LAmB (n=16) Echinocandin (n=12) Triazole (n=73)
Prednisone < 20 mg daily 7 7 51
Adverse event 1 0 1
Obtained triazole 4 1 N/A
Invasive fungal infection 3 2 4
Organ dysfunction 0 0 9
Other 1 2 3
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